ALK and non-small cell lung carcinoma: In 2020, based on the data from a phase III clinical trial, CheckMate 227, nivolumab in combination with ipilimumab was approved by the U.S. FDA for the treatment of advanced NSCLC whose PD‐L1 expression ≥1% and without EGFR or ALK mutation.